PAYS Stock Analysis: Paysign | NASDAQ
Software - Infrastructure | NASDAQ, USA | Market Cap: 667m USD | 12M Return: 108.8% | US70451A1043 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 9.98M
EPS Trend: 96.2%
Qual. Beats: -1
Rev. Trend: 99.2%
Qual. Beats: 6
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Paysign, Inc. is a U.S.-based provider of prepaid card programs, patient affordability solutions, digital banking, life science software technology, and integrated payment processing services for businesses, consumers, and government institutions. Its offerings span corporate rewards, prepaid gift cards, general-purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trial payments, healthcare reimbursement, pharmaceutical payment assistance, and demand deposit accounts accessible via debit card. The company also runs a customer service center and a communication suite that includes a mobile app, two-way SMS, text alerts, and a cardholder web portal, marketing its solutions under the Paysign brand. Paysign was founded in 2001 and is headquartered in Henderson, Nevada.
The company operates at the intersection of fintech and healthcare payments, with a notable focus on pharmaceutical patient assistance programs and clinical trial compensation-niches that leverage specialized payment infrastructure to meet regulatory and compliance requirements. Its model combines program management, card issuance, and proprietary software platforms, allowing it to capture revenue across card float, program fees, and processing services.
- Patient affordability segment accelerates pharmaceutical payment revenue growth
- Higher interest rates boost float income on prepaid card balances
- New corporate rewards and pharma contracts expand top-line growth
| Net Income: 15.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.21 > 0.02 and ΔFCF/TA 30.12 > 1.0 |
| NWC/Revenue: 34.36% < 20% (prev 22.46%; Δ 11.90% < -1%) |
| CFO/TA 0.22 > 3% & CFO 71.3m > Net Income 15.8m |
| Net Debt (-21.7m) to EBITDA (29.4m): -0.74 < 3 |
| Current Ratio: 1.14 > 1.5 & < 3 |
| Outstanding Shares: last quarter (62.0m) vs 12m ago 7.09% < -2% |
| Gross Margin: 56.18% > 18% (prev 59.99%; Δ -3.81% > 0.5%) |
| Asset Turnover: 39.40% > 50% (prev 35.35%; Δ 4.05% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.11 (Total Current Assets 283.0m - Total Current Liabilities 248.4m) / Total Assets 317.0m |
| B: 0.09 (Retained Earnings 27.3m / Total Assets 317.0m) |
| C: 0.08 (EBIT TTM 20.1m / Avg Total Assets 255.4m) |
| D: 0.23 (Book Value of Equity 60.2m / Total Liabilities 256.8m) |
| Altman-Z'' = 1.77 = BBB |
| DSRI: 1.71 (Receivables 103.5m/41.3m, Revenue 100.6m/68.5m) |
| GMI: 1.07 (GM 59.99% / 56.18%) |
| AQI: 0.52 (AQ_t 0.08 / AQ_t-1 0.16) |
| SGI: 1.47 (Revenue 100.6m / 68.5m) |
| TATA: -0.18 (NI 15.8m - CFO 71.3m) / TA 317.0m) |
| Beneish M = -2.35 (Cap -4..+1) = BBB |
As of September 21, 2026, the stock is trading at USD 12.34 with a total of 1,162,936 shares traded. Over the past week, the price has changed by -5.15%, over one month by -8.73%, over three months by +66.76% and over the past year by +108.80%.
Current recommended Stop Loss: 11.40 (which is 7.6% or 1.3 ATR below the current price).
Paysign has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy PAYS.
- StrongBuy: 3
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 13.5 | 9.4% |
P/E Trailing = 47.28
P/E Forward = 30.581
P/S = 6.6312
P/B = 11.4226
Revenue TTM = 100.6m USD
EBIT TTM = 20.1m USD
EBITDA TTM = 29.4m USD
Long Term Debt = 4.82m USD (estimated: total debt 5.71m - short term 891k)
Short Term Debt = 891k USD (from shortTermDebt, last quarter)
Debt = 5.71m USD (from shortLongTermDebtTotal, last quarter) (leases 5.71m already included)
Net Debt = -21.7m USD (calculated: Debt 5.71m - CCE 27.4m)
Enterprise Value = 645.7m USD (667.4m + Debt 5.71m - CCE 27.4m)
Interest Coverage Ratio = unknown (Ebit TTM 20.1m / Interest Expense TTM 0.0)
EV/FCF = 9.62x (Enterprise Value 645.7m / FCF TTM 67.1m)
FCF Yield = 10.39% (FCF TTM 67.1m / Enterprise Value 645.7m)
FCF Margin = 66.68% (FCF TTM 67.1m / Revenue TTM 100.6m)
Net Margin = 15.67% (Net Income TTM 15.8m / Revenue TTM 100.6m)
Gross Margin = 56.18% ((Revenue TTM 100.6m - Cost of Revenue TTM 44.1m) / Revenue TTM)
Gross Margin QoQ = 63.35% (prev 55.58%)
Tobins Q-Ratio = 2.04 (Enterprise Value 645.7m / Total Assets 317.0m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 5.71m)
Taxrate = 21.58% (4.34m / 20.1m)
NOPAT = 15.8m (EBIT 20.1m * (1 - 21.58%))
Current Ratio = 1.14 (Total Current Assets 283.0m / Total Current Liabilities 248.4m)
Debt / Equity = 0.09 (Debt 5.71m / totalStockholderEquity, last quarter 60.2m)
Debt / EBITDA = -0.74 (Net Debt -21.7m / EBITDA 29.4m)
Debt / FCF = -0.32 (Net Debt -21.7m / FCF TTM 67.1m)
Total Stockholder Equity = 52.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.17% (Net Income 15.8m / Total Assets 317.0m)
RoE = 30.13% (Net Income TTM 15.8m / Total Stockholder Equity 52.4m)
RoCE = 35.18% (EBIT 20.1m / Capital Employed (Equity 52.4m + L.T.Debt 4.82m))
RoIC = 24.49% (NOPAT 15.8m / Invested Capital 64.4m)
WACC = 12.59% (E(667.4m)/V(673.1m) * Re(12.70%) + D(5.71m)/V(673.1m) * Rd(0.0%) * (1-Tc(0.22)))
Discount Rate = 12.70% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 89.69 | Cagr: 5.65%
[DCF] Terminal Value 62.09% ; FCFF base≈67.1m ; Y1≈67.4m ; Y5≈71.4m
[DCF] Fair Price = 11.81 (EV 645.3m - Net Debt -21.7m = Equity 666.9m / Shares 56.5m; r=12.59% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: 96.25 | EPS CAGR: 96.74% | SUE: -1.27 | # QB: -1
Revenue Correlation: 99.18 | Revenue CAGR: 33.67% | SUE: 2.78 | # QB: 6
EPS current Quarter (2026-09-30): EPS=0.13 | Chg30d=+0.00% | Revisions=+40% | Analysts=2
EPS current Year (2026-12-31): EPS=0.49 | Chg30d=+0.00% | Revisions=+40% | GrowthEPS=+276.9% | GrowthRev=+39.8%
EPS next Year (2027-12-31): EPS=0.60 | Chg30d=+0.00% | Revisions=+40% | GrowthEPS=+23.5% | GrowthRev=+16.2%
[Analyst] Revisions Ratio: +67% (up=6, down=0)